Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jul;85(2):141–146. doi: 10.1054/bjoc.2001.1897

A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01)

A Riccardi 1, P Pugliese 1, M Danova 1, S Brugnatelli 1, D Grasso 1, M Giordano 2, G Bernardo 3, G Giardina 4, S Fava 5, G Montanari 6, C Pedrotti 7, G Trotti 8, E Rinaldi 9, M A Poli 10, C Tinelli 11
PMCID: PMC2364040  PMID: 11461067

Abstract

Sequential administration of the association of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel could be better tolerated than the association of an anthracycline and paclitaxel while having a similar antitumour effect. 69 patients with advanced breast cancer previously untreated with anthracyclines or paclitaxel entered a phase II multicentre study in which FEC was followed by paclitaxel. Both regimens were administered 4 times every 21 days. The median follow-up is 20 months and 38/69 patients have died. Grade III–IV toxicity was acceptable. Leukopenia occurred in 26% of patients, thrombocytopenia in 2% and anaemia in 4%. One patient had reversible heart failure during FEC therapy. Peripheral neuropathy and arthralgia-myalgia occurred in 9% and 4% of patients, respectively and one patient had respiratory hypersensitivity during paclitaxel treatment. 9 patients did not complete therapy because of: treatment refusal (n= 1), cardiac toxicity (n= 1), early death during FEC chemotherapy (n= 1), major protocol violations (n= 4), hypersensitivity reaction (n= 1) and early death during paclitaxel chemotherapy (n= 1). The overall response rate was 65% (95% CI = 53–76), and 7% of patients had stable disease. Therapy was defined as having failed in 28% of patients because they were not evaluable (13%) or had progressive disease (15%). The median time to progression and survival are 13.2 and 23.5 months, respectively. Sequential FEC-paclitaxel is a suitable strategy for patients with metastatic breast cancer who have not been previously treated with anthracyclines and/or taxanes. In fact, it avoids major haematologic toxicity and has a good antitumour effect. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: advanced breast cancer, anthracycline-containing regimen, paclitaxel, sequential chemotherapy

Full Text

The Full Text of this article is available as a PDF (68.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Batel-Copel L. M., Kornblith A. B., Batel P. C., Holland J. C. Do oncologists have an increasing interest in the quality of life of their patients? A literature review of the last 15 years. Eur J Cancer. 1997 Jan;33(1):29–32. doi: 10.1016/s0959-8049(96)00414-5. [DOI] [PubMed] [Google Scholar]
  2. Biganzoli L., Piccart M. J. The bigger the better? ... or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer. Ann Oncol. 1997 Dec;8(12):1177–1182. doi: 10.1023/a:1008295432012. [DOI] [PubMed] [Google Scholar]
  3. Bishop J. F., Dewar J., Toner G. C., Smith J., Tattersall M. H., Olver I. N., Ackland S., Kennedy I., Goldstein D., Gurney H. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol. 1999 Aug;17(8):2355–2364. doi: 10.1200/JCO.1999.17.8.2355. [DOI] [PubMed] [Google Scholar]
  4. Cocconi G., Bisagni G., Bella M., Acito L., Anastasi P., Carpi A., Di Costanzo F., Frassoldati A., Mosconi A., Borrini A. Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study. Am J Clin Oncol. 1999 Dec;22(6):593–600. doi: 10.1097/00000421-199912000-00010. [DOI] [PubMed] [Google Scholar]
  5. Coombes R. C., Bliss J. M., Wils J., Morvan F., Espié M., Amadori D., Gambrosier P., Richards M., Aapro M., Villar-Grimalt A. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol. 1996 Jan;14(1):35–45. doi: 10.1200/JCO.1996.14.1.35. [DOI] [PubMed] [Google Scholar]
  6. Curran D., Aaronson N., Standaert B., Molenberghs G., Therasse P., Ramirez A., Koopmanschap M., Erder H., Piccart M. Summary measures and statistics in the analysis of quality of life data: an example from an EORTC-NCIC-SAKK locally advanced breast cancer study. Eur J Cancer. 2000 May;36(7):834–844. doi: 10.1016/s0959-8049(00)00056-3. [DOI] [PubMed] [Google Scholar]
  7. Falkson G., Gelman R. S., Pandya K. J., Osborne C. K., Tormey D., Cummings F. J., Sledge G. W., Abeloff M. D. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol. 1998 May;16(5):1669–1676. doi: 10.1200/JCO.1998.16.5.1669. [DOI] [PubMed] [Google Scholar]
  8. Fossati R., Confalonieri C., Torri V., Ghislandi E., Penna A., Pistotti V., Tinazzi A., Liberati A. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol. 1998 Oct;16(10):3439–3460. doi: 10.1200/JCO.1998.16.10.3439. [DOI] [PubMed] [Google Scholar]
  9. Gehl J., Boesgaard M., Paaske T., Jensen B. V., Dombernowsky P. Paclitaxel and doxorubicin in metastatic breast cancer. Semin Oncol. 1996 Dec;23(6 Suppl 15):35–38. [PubMed] [Google Scholar]
  10. Holmes F. A., Walters R. S., Theriault R. L., Forman A. D., Newton L. K., Raber M. N., Buzdar A. U., Frye D. K., Hortobagyi G. N. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991 Dec 18;83(24):1797–1805. doi: 10.1093/jnci/83.24.1797-a. [DOI] [PubMed] [Google Scholar]
  11. Levine M. N., Bramwell V. H., Pritchard K. I., Norris B. D., Shepherd L. E., Abu-Zahra H., Findlay B., Warr D., Bowman D., Myles J. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998 Aug;16(8):2651–2658. doi: 10.1200/JCO.1998.16.8.2651. [DOI] [PubMed] [Google Scholar]
  12. Muss H. B., Case L. D., Richards F., 2nd, White D. R., Cooper M. R., Cruz J. M., Powell B. L., Spurr C. L., Capizzi R. L. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med. 1991 Nov 7;325(19):1342–1348. doi: 10.1056/NEJM199111073251904. [DOI] [PubMed] [Google Scholar]
  13. Nabholtz J. M., Gelmon K., Bontenbal M., Spielmann M., Catimel G., Conte P., Klaassen U., Namer M., Bonneterre J., Fumoleau P. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 1996 Jun;14(6):1858–1867. doi: 10.1200/JCO.1996.14.6.1858. [DOI] [PubMed] [Google Scholar]
  14. Nabholtz J. M., Senn H. J., Bezwoda W. R., Melnychuk D., Deschênes L., Douma J., Vandenberg T. A., Rapoport B., Rosso R., Trillet-Lenoir V. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol. 1999 May;17(5):1413–1424. doi: 10.1200/JCO.1999.17.5.1413. [DOI] [PubMed] [Google Scholar]
  15. Pazos C., Mickiewicz E., Di Notto M. R., Cóppola F., Ventriglia M., Jovtis S., Balbiani L., Lewi D., Róndinón M., Témperley G. Phase II of doxorubicin/taxol in metastatic breast cancer. Argentine Multicenter Taxol Group. Breast Cancer Res Treat. 1999 May;55(1):91–96. doi: 10.1023/a:1006194909859. [DOI] [PubMed] [Google Scholar]
  16. Pivot X., Asmar L., Hortobagyi G. N. The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review). Int J Oncol. 1999 Aug;15(2):381–386. [PubMed] [Google Scholar]
  17. Rahman Z. U., Frye D. K., Smith T. L., Asmar L., Theriault R. L., Buzdar A. U., Hortobagyi G. N. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer. 1999 Jan 1;85(1):104–111. doi: 10.1002/(sici)1097-0142(19990101)85:1<104::aid-cncr15>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  18. Reichman B. S., Seidman A. D., Crown J. P., Heelan R., Hakes T. B., Lebwohl D. E., Gilewski T. A., Surbone A., Currie V., Hudis C. A. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol. 1993 Oct;11(10):1943–1951. doi: 10.1200/JCO.1993.11.10.1943. [DOI] [PubMed] [Google Scholar]
  19. Riccardi A., Tinelli C., Brugnatelli S., Pugliese P., Giardina V., Giordano M., Danova M., Richetti A., Fava S., Rinaldi E. Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: a prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer. Int J Oncol. 2000 Apr;16(4):769–776. doi: 10.3892/ijo.16.4.769. [DOI] [PubMed] [Google Scholar]
  20. Rischin D., Smith J., Millward M., Lewis C., Boyer M., Richardson G., Toner G., Gurney H., McKendrick J. A phase II trial of paclitaxel and epirubicin in advanced breast cancer. Br J Cancer. 2000 Aug;83(4):438–442. doi: 10.1054/bjoc.2000.1306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Rivera E., Holmes F. A., Frye D., Valero V., Theriault R. L., Booser D., Walters R., Buzdar A. U., Dhingra K., Fraschini G. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer. 2000 Dec 1;89(11):2195–2201. doi: 10.1002/1097-0142(20001201)89:11<2195::aid-cncr7>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  22. Sparano J. A., Hu P., Rao R. M., Falkson C. I., Wolff A. C., Wood W. C. Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1999 Dec;17(12):3828–3834. doi: 10.1200/JCO.1999.17.12.3828. [DOI] [PubMed] [Google Scholar]
  23. Venturini M., Lunardi G., Del Mastro L., Vannozzi M. O., Tolino G., Numico G., Viale M., Pastrone I., Angiolini C., Bertelli G. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. J Clin Oncol. 2000 May;18(10):2116–2125. doi: 10.1200/JCO.2000.18.10.2116. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES